Advertisement

Picture Berlin Partner Bionnale 2023 the Life Sciences Event 650x100px
Financing › Details

MyCellHub–SEVERAL: investment, 202212 financing round €2m with Gemma Frisius Fund + Noshaq + The Factory Fund + LRM

 

Period Period 2022-12-08
Organisations Money taker MyCellHub N.V.
  Group MyCellHub (Group)
  Money source SEVERAL
Product Product  venture capital
Person Person Stragier, Patrick (Promethera 201512– VP Operations before Solvay + DSM Biologics + Genzyme + Lonza + MaSTherCell)
     

MyCellHub N.V.. (12/15/22). "Press Release: MyCellHub Raises EUR 2 Million and Incorporates in US to Help Biotech Manufacturing Become More Intelligent". Hasselt.

MyCellHub, a Belgium-based software company delivering an intelligent software platform to optimize complex bio-manufacturing workflows, has successfully closed a 2 million euro capital round to further support its growth. This capital increase allows MyCellHub to further expand internationally by opening a US subsidiary and rolling out its cleanroom cleaning module to new international customers.

“I am very pleased to see significant growth - both in terms of our financial backing and depth in international markets,” says CEO Jacques Parlongue. “Our team has worked hard to put forward solutions that can truly shift cell and gene therapies manufacturing towards the use of smart digital tools, and I'm excited that with this financing round we will further be able to expand.”


Stable Growth with an Additional EUR 2 Million Investment

The new EUR 2 million investment comes from MyCellHub’s current investors Gemma Frisius, Noshaq, and The Faktory Fund as well as new investor LRM. The round was formalized in an official signing ceremony on December 8th.

“We believe in MyCellHub’s potential,” says Dries Bauters of LRM. “There is a big opportunity in the market with about 90% of bio-manufacturing still relying on paper-based solutions. This leads to errors, inefficient workflows, and difficult quality controls. MyCellHub aims to resolve these issues to make bio-manufacturing safer and more reliable.”

Patrick Stragier from Noshaq explains: “Going digital for cell and gene therapies means they can more easily scale. Operations, quality, and IT can more efficiently work together within their disciplines and across teams so they can ultimately help more patients access life-saving treatments.”


Market Growth: US Opening and Cleanroom Cleaning Advancement

MyCellHub Inc. has now been officially established in the United States to make it easier for US-based customers to work with MyCellHub. “Opening in the US is a big step forward towards our goal of making it easier for American companies to use our digital services,” says MyCellHub Co-Founder Toon Lambrechts. “We have seen interest from the US market and want to make it as straightforward as possible for new companies to sign up.”

Plus, MyCellHub is deepening its entrance to the cleanroom cleaning market with new customers in the sector who are benefiting from its interactive work instructions, masterplan management, smart data collection and real-time recording.

Vanessa Morini, CEO of cleanroom cleaning company TRU says, “Since starting with MyCellHub, we’ve been able to streamline our services. Our operators have a reliable way of knowing what to do when, which prevents errors and saves time. And since the data is digital and accessible from anywhere, sign-off is easy, saving even more time and making it easier to detect mistakes. We are making new plans to scale thanks to the savings with this platform.”


About MyCellHub

MyCellHub’sagile data management platform is meant for bio-manufacturers to reduce errors, streamline GMP compliance and enhance workflows to increase the accessibility to cell and gene therapies. Through its software-as-a-service (SaaS) platform, MyCellHub makes it easy for companies to scale by digitizing electronic batch records, inventory management, cleanroom cleaning and environmental monitoring. Unlock insights for life-transforming treatments at https://mycellhub.com


About LRM

LRM is an investment company that develops and stimulates economic growth in Limburg. We provide a solid basis so that companies and projects that create jobs in Limburg can grow. Our financial resources and expertise, together with the assets of Limburg, provide a unique breeding ground. More information: www.lrm.be


About The Faktory Fund

The Faktory Fund is an early-stage private equity fund founded by Pierre L'Hoest, former CEO and founder of EVS Broadcast Equipment, and Simon Alexandre (CETIC, Nest'Up). The Faktory Fund supports digital start-ups developing disruptive technologies that enable new products to take global leadership in B2B markets related to the Internet of Things (IoT) and Software as a Service (SaaS), located mainly in BeNeLux and France. More information: www.thefaktory.com


About CoFoundry nv

With a passion for innovation, we help entrepreneurs transform their ideas into sustainable companies by funding them in a seed stage and by coaching them in the growth process. We aim for the long run rather than a fast monetary return. Some say we cut through the funding hype and work hard to give your business a sustainable future. More information: http://www.thecofoundry.co


About Noshaq

Noshaq is a Belgian investment fund and project developer with a portfolio of 464 companies and 600 million euros of resources. Noshaq is the reference financial partner for the creation and development of SMEs in the Liege Region (Wallonia). Over the years, Noshaq has developed a range of financing vehicles in line with the needs and trends of the market and its strategy. Each service offered by Noshaq (capital - loan - leasing) is always determined according to the demand and needs of the owner-investor. The objective is always to have a leverage effect on the company's development. More info: www.noshaq.be


About Gemma Frisius Fund

Gemma Frisius Fund (GFF) is a seed capital fund, established in 1997 as a joint venture between KU Leuven, KBC Private Equity and BNP Paribas Fortis Private Equity. It combines the research and technology transfer expertise of the university with the financial and investment expertise of the two financial partners. GFF provides seed capital in the early development phases of innovative, research-based spin-off companies originating from all technology domains and provides support in their further growth process. More information: http://lrd.kuleuven.be/en/spinoff/gemma-frisius-fund


Contact

Jacques Parlongue, CEO
jacques.parlongue@mycellhub.com
+32 478.82.57.17

   
Record changed: 2022-12-15

Advertisement

Picture [iito] No Tracking 650x100px

More documents for MyCellHub (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Bionnale 2023 the Life Sciences Event 650x300px




» top